E-LIB Suche - Ergebnisse für: Pulsoni A

1

THE IELSG39 TRIAL: EFFICACY OF FIRST‐LINE CHLAMYDIA PSITTAC..:

Ferreri, A. J. M. ; Sassone, M. C. ; Cangi, M. G....
Hematological Oncology. 41 (2023) S2 - p. 106-107 , 2023

Link: https://doi.org/10.1002/..

2

COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG..:

Ferrero, S. ; Assanto, G. M. ; Durmo, R....
Hematological Oncology. 41 (2023) S2 - p. 183-185 , 2023

Link: https://doi.org/10.1002/..

3

Early clearance of hairy cell leukaemia in the bone marrow ..:

Ligia, S. ; Passucci, M. ; Assanto, G. M....
British Journal of Haematology. 204 (2023) 4 - p. 1288-1292 , 2023

Link: https://doi.org/10.1111/..

4

The impact of spleen metabolic tumor volume on total metabo..:

Guerra, L. ; Chauvie, S. ; Marcheselli, L....
Hematological Oncology. 41 (2023) S2 - p. 339-340 , 2023

Link: https://doi.org/10.1002/..

5

MARGINAL ZONE LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (MZL‐..:

Luminari, S. ; Bommier, C. ; Fabbri, N....
Hematological Oncology. 41 (2023) S2 - p. 102-103 , 2023

Link: https://doi.org/10.1002/..

6

Prognostic value of the end of induction PET in patients wi..:

Guerra, L. ; Bergesio, F. ; Fallanca, F....
Hematological Oncology. 41 (2023) S2 - p. 378-378 , 2023

Link: https://doi.org/10.1002/..

7

FRONTLINE INTENSIFIED ABVD DEMONSTRATES SUPERIOR EFFICACY T..:

Pinto, A. ; Corazzelli, G. ; Evangelista, A....
Hematological Oncology. 41 (2023) S2 - p. 31-33 , 2023

Link: https://doi.org/10.1002/..

8

EARLY METABOLIC RESPONSE IN FOLLICULAR LYMPHOMA: A SUBSET A..:

Luminari, S. ; Guerra, L. ; Durmo, R....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

9

BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS STEM CEL..:

Massaro, F. ; Pavone, V. ; Stefani, P. M....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

10

THE ROLE OF END OF TREATMENT PET CT EVALUATED BY DEAUVILLE ..:

Assanto, G. M. ; Agrippino, R. ; Lapietra, G....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

11

FAVOURABLE PROGNOSTIC ROLE OF HIGH BASAL MAXIMAL STANDARDIZ..:

Assanto, G. M. ; Ciotti, G. ; Brescini, M....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

12

UPDATED RESULTS OF THE FIL "MIRO" STUDY, A MULTICENTER PHAS..:

Pulsoni, A. ; Tosti, M. E. ; Ferrero, S....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

13

RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPH..:

Luminari, S. ; Galimberti, S. ; Versari, A....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

14

DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOC..:

Merli, M. ; Rattotti, S. ; Spina, M....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

15

PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A..:

Pirosa, M. C. ; Orsucci, L. ; Feugier, P....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..